A detail study of corona vaccine effect on cancer patients

Abstract

Author(s): Poonam Joshi*, Kapil Kalra and Deepika Ghalwan

Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) is highly communicable and pathogenic coronavirus that come out in December 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID 19), which intimidate public health and safety. According to World Health Organization (WHO), infection is known as COVID-19. With the start of the COVID-19 pandemic, 10 vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has generated excitement and arrives at a time of great need, as the number of COVID-19 cases worldwide continues to rapidly increase. Two vac-cines are currently approved for full use, both built on mRNA and lipid nanotechnology platforms, a success story of mRNA technology 20 years for making. For cancer patients, questions put up for the safety and efficacy of these vaccines in the setting of immune alterations engendered by their therapies. We discuss in this article on leading COVID-19 vaccine candidates and vaccination of patients.

Share this article